Skip to Main Content

4,421

Views

29

CrossRef citations to date

0

Altmetric

Original Articles

Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Sven de Vosa David Geffen School of Medicine at UCLA, Los Angeles, CA, USACorrespondence[email protected]
View further author information

,

John P. Leonardb Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, USAView further author information

,

Jonathan W. Friedbergc Wilmot Cancer Institute, University of Rochester, Rochester, NY, USAView further author information

,

Jasmine Zaind City of Hope Comprehensive Cancer Center, Duarte, CA, USAView further author information

,

Kieron Dunleavye George Washington University, Washington, DC, USAView further author information

,

Rod Humerickhousef AbbVie, Inc, North Chicago, IL, USAView further author information

,

John Hayslipf AbbVie, Inc, North Chicago, IL, USAView further author information

,

John Peskof AbbVie, Inc, North Chicago, IL, USAView further author information

&

Wyndham H. Wilsone George Washington University, Washington, DC, USAView further author information